2026-06-30 · antidepressants, SSRI, SNRI, mirtazapine, bupropion, weight gain, weight loss · 11 min read

Which antidepressant causes the most weight gain?

Mirtazapine and amitriptyline produce the largest average weight gain across long-term cohorts — typically 2 to 5 kg at 12 months for mirtazapine and 2 to 4 kg for amitriptyline (Watanabe 2011 Cochrane review; Serretti 2010 meta-analysis in the Journal of Clinical Psychiatry). Both work in part through H1-histamine receptor blockade, which stimulates appetite. Within SSRIs, paroxetine is the consistent outlier, with 1 to 3 kg of average gain over a year (Wong 2021 in JAMA Psychiatry). Do not stop or switch a medication based on these numbers — the right antidepressant is the one your depression or anxiety responds to. Bring the weight concern to the prescribing clinician so a within-class or class switch can be discussed safely.

Which antidepressant is best for weight loss?

Bupropion is the only commonly used antidepressant associated with mild weight loss — typically 1 to 2 kg over 12 months (Anderson 2002 in Obesity Research; Petimar 2024 in the Annals of Internal Medicine). It is also one of the two components of the FDA-approved naltrexone-bupropion combination (Contrave) used specifically for weight management. Bupropion is contraindicated in patients with seizure disorders, active or remitted bulimia or anorexia nervosa, and those tapering alcohol or benzodiazepines. Fluoxetine is the most weight-favorable SSRI but is still essentially neutral, not loss-promoting. None of these medications are weight-loss drugs in the way a GLP-1 is — they are antidepressants chosen for a depression or anxiety indication that happen to be weight-friendly.

Is paroxetine the worst SSRI for weight?

Yes — across multiple long-term cohorts, paroxetine is the SSRI most consistently associated with weight gain, typically 1 to 3 kg over 12 months and more at 2 to 5 years (Gafoor 2018 BMJ UK CPRD cohort; Wong 2021 JAMA Psychiatry). Sertraline, escitalopram, citalopram, and fluoxetine all run roughly neutral or with only minimal average gain. Paroxetine's stronger anticholinergic and antihistamine activity is the likely mechanism. Paroxetine is also FDA-approved for hot-flash treatment (Brisdelle), which sometimes brings it into a population particularly weight-concerned. If you are on paroxetine for vasomotor symptoms or for an anxiety or depression indication and gaining weight, a within-class switch (paroxetine to sertraline or escitalopram) is the conversation to have with the prescriber.

Can I take a GLP-1 with my antidepressant?

For most patients, yes — and the combination is increasingly common in 2026. The Wadden 2024 JAMA Internal Medicine post-hoc analysis of the SELECT trial covering more than 17,000 participants on semaglutide 2.4 mg found no increase in suicidal ideation, depression, or other psychiatric adverse events versus placebo over more than 3 years of follow-up, including in patients on baseline antidepressants. Practical considerations: tell your prescriber about both medications so they can coordinate; weight loss can shift antidepressant blood levels and may require a dose check; nausea on GLP-1 initiation can interact with the gastrointestinal side effects of SSRIs and SNRIs in the first weeks; and patients with active suicidality, anorexia nervosa, or bulimia should not be on a GLP-1 without specialist input. Never start a GLP-1 by stopping your antidepressant first.

How long should I wait before deciding the drug is making me gain weight?

At least 8 to 12 weeks of stable dosing, and ideally longer. The reason is that depression and severe anxiety themselves often suppress appetite — melancholic-pattern depression in particular drives meaningful weight loss before treatment (Stunkard 1990 Archives of General Psychiatry; the STAR*D 2006 program documented similar patterns). Some of what looks like 'antidepressant weight gain' in the first 3 months is actually appetite normalization as the depression remits. Sustained gain that continues past 3 to 6 months at stable dose is more likely a drug effect. Track weight weekly, not daily, and bring the trajectory to your prescriber rather than reacting to short-term fluctuations.

Is the weight gain actually depression remission?

Often, yes — at least in part. Major depressive disorder with melancholic features classically suppresses appetite and produces meaningful weight loss before treatment; the Stunkard 1990 work and the STAR*D 2006 program both showed appetite and weight normalizing as depressive symptoms improved. Atypical-pattern depression is the opposite — it produces hyperphagia and weight gain at baseline that then responds to treatment. So the same antidepressant can look 'weight-gaining' in a melancholic patient and 'weight-losing' in an atypical one. Three to six months of stable dosing is usually enough to separate remission-related appetite normalization from drug-driven gain. The honest framing — which good prescribers will give you — is 'we expect some weight gain as you feel better; we will reassess at 3 months.'

Can I take bupropion if I've had an eating disorder?

Bupropion is contraindicated in patients with active or remitted bulimia nervosa and anorexia nervosa per the FDA label, because both conditions carry an elevated seizure risk that bupropion compounds (Davidson 1989 Journal of Clinical Psychiatry; APA 2023 eating-disorder guideline). The contraindication is absolute in the US labeling, so a prescriber will almost always choose a different antidepressant — most commonly sertraline or fluoxetine, which both have evidence in binge eating disorder. If you have a remote history of an eating disorder that is fully resolved with no recent symptoms, the decision is individualized and should involve a clinician familiar with both your eating-disorder history and your current depression or anxiety picture.

Should I switch to bupropion?

Maybe — but the decision is a clinical one, not a self-directed one. Bupropion is a reasonable consideration if you have gained more than 5 percent of body weight on an SSRI or SNRI, your current depression is in stable remission, you have no seizure-disorder or eating-disorder history, and you and your prescriber agree the weight effect outweighs the risk of changing a working regimen. It is not a good fit for patients with anxiety as a primary symptom — bupropion can be activating and worsen panic — or for those on certain interacting medications. The Petimar 2024 Annals of Internal Medicine comparative cohort confirmed bupropion's weight advantage relative to the other 7 most-prescribed antidepressants. Bring the table to your prescriber rather than asking for the switch by name.

Antidepressants and Weight: Which Cause Gain, Which Don’t

Quick stats

• US adults on at least one antidepressant: ~13%; UK adults ~21% (Gafoor 2018 BMJ)
• 12-month weight change on mirtazapine: +2 to +5 kg (Watanabe 2011 Cochrane)
• 12-month weight change on bupropion: −1 to −2 kg (Anderson 2002 Obesity Research)
• Between-class spread at 12 months: ~5–7 kg (Serretti 2010 meta-analysis)
• 988 Suicide & Crisis Lifeline: call or text 988 (US) for any thoughts of self-harm

The honest picture, in one paragraph

Antidepressants are not interchangeable for body weight. Gafoor 2018 (BMJ) tracked nearly 300,000 UK adults in the CPRD database and found 5-year weight trajectories that varied by 3 to 4 kg depending on the drug. Wong 2021 (JAMA Psychiatry) and Petimar 2024 (Annals of Internal Medicine) — the largest head-to-head cohort to date — confirmed the same ordering: mirtazapine, paroxetine, and amitriptyline produce the most gain; bupropion produces mild loss; sertraline, escitalopram, citalopram, fluoxetine, and the SNRIs sit in between, with a 5 to 7 kg between-class spread over a year (Serretti 2010 meta-analysis). None of this should drive you to stop or switch a working medication on your own — abrupt discontinuation can precipitate withdrawal and relapse.

The relationship between mood and weight also runs both ways. Untreated depression and severe anxiety often distort eating — toward restriction (melancholic pattern) or toward hyperphagia (atypical pattern). Some weight change in the first 3 months on a new antidepressant is the disease remitting, not the drug acting. The depression and weight loss and anxiety and weight loss guides cover the bidirectional dynamics.

How antidepressants are organized

Six main classes are in clinical use in 2026. Receptor profile — particularly H1 histamine and 5HT2C serotonin activity — predicts most of the weight effect.

If your prescribing picture involves additional mood-stabilizer or antipsychotic medication, the cluster guides for bipolar disorder and weight loss and schizophrenia, antipsychotics, and weight loss cover how those layers compound the weight effect.

Why some antidepressants drive weight gain and others don’t

1. H1 histamine-receptor blockade is the single biggest driver

Kroeze 2003 (Neuropsychopharmacology) mapped the H1 receptor-binding affinity of dozens of psychiatric medications and showed it correlates almost linearly with clinical weight gain. Mirtazapine, amitriptyline, doxepin, and — among SSRIs — paroxetine all have meaningful H1 affinity and stimulate appetite. This is the biology behind nighttime carbohydrate cravings on mirtazapine and persistent hunger on amitriptyline. The emotional eating and mindful eating for weight loss guides cover managing appetite stimulation without restriction.

2. 5HT2C receptor blockade is the second driver, especially in tricyclics

Reynolds 2002 (Lancet) described the 5HT2C–leptin signaling pathway: antagonism reduces satiety signaling and raises set-point. This is the dominant mechanism for the larger gains on tricyclics and on atypical antipsychotics layered onto antidepressants. The set point theory of weight loss overview covers the practical glide path.

3. Treating depression itself reverses appetite suppression — some “drug-induced” gain is remission

Stunkard 1990 (Archives of General Psychiatry) and STAR*D 2006 both documented baseline appetite loss in melancholic depression that normalizes with treatment. A patient who lost 6 kg before starting an SSRI and regains 4 kg in the first 3 months has not necessarily had a drug-driven gain — they have had appetite return as the depression remitted.

4. Co-prescribed medications and inactivity matter at least as much

Real-world weight gain on an antidepressant rarely happens in isolation. Co-prescribed second-generation antipsychotics — aripiprazole, brexpiprazole, quetiapine, olanzapine — add meaningfully (Allison 1999). Gabapentinoids and lithium (Bowden 2008 Bipolar Disord) do the same. The bipolar, schizophrenia, and sleep, stress, and weight management guides cover the layered picture.

How much each drug typically shifts weight

This table is the honest 2026 lookup. Use it for conversation with your prescriber — not for self-directed switching.

5-step antidepressant-and-weight protocol

Step 1: Never stop or change an antidepressant on your own

Cipriani 2018 (Lancet) and the APA 2010 depression guideline are blunt: abrupt discontinuation can trigger withdrawal and relapse, and relapse risk in the first 6 months after self-stopping is substantially higher than with continued treatment. The protocol begins with a clinician conversation, not a pill cut. If you have any thoughts of self-harm, call or text 988.

Step 2: Establish the actual weight trajectory before attributing gain to the drug

Track weekly weight for 8 to 12 weeks of stable dosing before drawing a conclusion. Early gain can be appetite normalizing as the depression remits; sustained gain past 3 to 6 months at stable dose is more likely a drug effect. The weight loss plateau and non-scale victories guides cover what else to look at.

Step 3: If gain exceeds 5% of body weight at 6 months, discuss a within-class switch first

Gafoor 2018 and Petimar 2024 both show that within-class switches — paroxetine to sertraline, amitriptyline to nortriptyline — preserve response while reducing the weight effect. This is the lowest-risk change because it keeps the mechanism familiar to a depression already responding.

Step 4: If within-class change is not appropriate, consider a class switch to bupropion or fluoxetine

Anderson 2002 and Petimar 2024 both support bupropion and fluoxetine as the most weight-favorable options. The decision should include depression subtype (bupropion can worsen comorbid anxiety), eating-disorder history (contraindicated), and seizure risk. The GLP-1 medications compared and weight loss drug safety guides cover when adding a weight-loss medication beats a class switch.

Step 5: Anchor parallel weight work on structured routines — never radical restriction

Carbone 2021 (Journal of Affective Disorders) showed that aggressive restriction worsens depressive symptoms and raises eating-disorder risk in patients with a mood-disorder history. The protocol is the same that holds everywhere: 7–9 hours of sleep, 7,000–10,000 steps a day, balanced meals at regular clock times, and 1.0–1.2 g/kg protein. See behavioral therapy for weight loss, walking for weight loss, and binge eating disorder and weight loss.

What treatments actually do — comparison

Special situations

Antidepressants in bipolar disorder, schizophrenia, and co-prescribed antipsychotics

Antidepressant monotherapy in bipolar disorder is rarely appropriate — it can precipitate mania and rapid-cycling, and APA and CANMAT guidelines anchor treatment on a mood stabilizer (lithium, valproate, lamotrigine) or a second-generation antipsychotic. Bowden 2008 (Bipolar Disord) reviewed lithium’s metabolic profile — modest weight gain (~2 kg at 12 months) and thyroid effects that compound any antidepressant weight effect. When a second-generation antipsychotic is added for treatment-resistant depression (aripiprazole, brexpiprazole, and quetiapine are common adjuncts), the metabolic-monitoring protocol from schizophrenia and weight loss applies, including the Wu 2008 JAMA evidence for adjunctive metformin. The bipolar and weight loss guide covers the mood-stabilizer side.

Antidepressants in patients with eating disorders or eating-disorder history

The APA 2023 eating-disorder guideline is firm on two points. First, bupropion is contraindicated in active or remitted bulimia and anorexia nervosa because of seizure risk (Davidson 1989 J Clin Psychiatry). Second, sertraline and fluoxetine have the strongest evidence in binge eating disorder; fluoxetine is FDA-approved for bulimia at 60 mg/day. Restrictive eating, purging, or compulsive exercise that starts after a medication change is a high-priority signal. See binge eating disorder and weight loss and anorexia recovery and weight restoration.

Antidepressants in perimenopause, postpartum, and hot-flash treatment

Perimenopausal depression often coincides with vasomotor symptoms, sleep disruption, and the body-composition shift toward visceral fat. Stuenkel 2015 (Journal of Clinical Endocrinology & Metabolism) reviewed non-hormonal options — paroxetine (Brisdelle), venlafaxine, escitalopram, and gabapentin are first-line. Paroxetine is the highest-weight-gain SSRI, so venlafaxine or escitalopram is often the more weight-friendly choice with similar hot-flash benefit. Postpartum depression affects ~1 in 7 birthing parents; sertraline is generally preferred while breastfeeding. See menopause and weight loss, weight loss after pregnancy, and Hashimoto’s thyroiditis and weight loss.

Red flags — when to see a doctor

If you are having thoughts of self-harm or suicide, call or text 988 (Suicide & Crisis Lifeline) right now, or go to the nearest emergency department.

• Worsening depression, suicidal ideation, or self-harm during a switch or taper — urgent psychiatric evaluation; call 988.
• Rapid weight gain greater than 5% in 3 months on a new antidepressant — within-class switch discussion with prescriber.
• Restrictive eating, purging, or compulsive exercise after a weight conversation — see anorexia recovery and weight restoration.
• New-onset binge eating — see binge eating disorder and weight loss.
• Persistent dry mouth, blurred vision, urinary retention, or constipation on a tricyclic — anticholinergic-burden review.
• New seizure on bupropion — urgent neurology and psychiatry evaluation (Davidson 1989 J Clin Psychiatry).

Antidepressants and Weight FAQ

Which antidepressant causes the most weight gain? Mirtazapine and amitriptyline; paroxetine is the SSRI outlier.

Which antidepressant is best for weight loss? Bupropion — mild loss of 1 to 2 kg over 12 months.

Is paroxetine the worst SSRI for weight? Yes — 1 to 3 kg gain on average.

Can I take a GLP-1 with my antidepressant? For most patients yes; coordinate prescribers.

How long should I wait before deciding the drug is making me gain weight? At least 8 to 12 weeks of stable dosing.

Is the weight gain actually depression remission? Often partly yes — melancholic depression suppresses appetite and remission normalizes it.

Can I take bupropion if I’ve had an eating disorder? No — contraindicated in active or remitted bulimia and anorexia.

Should I switch to bupropion? Discuss with your prescriber if you have gained more than 5 percent on an SSRI or SNRI with stable mood.